Henlius’ global innovation center (GIC) is dedicated to build a comprehensive and efficient innovative R&D system, covering molecular informatics, protein discovery, translational biology, pre-clinical development, biomarkers, etc. Focusing on unmet medical demands of patients, GIC actively promotes project initiation and management mechanisms for early innovative projects, continues to explore new targets and mechanisms with antibody technology as a core. Currently, the company’s portfolio has more than 50 molecules including monoclonal antibody (mAb), multispecific antibody, antibody-drug conjugate (ADC), fusion protein, small molecule drug, mRNA, etc., broadly covering therapeutic areas such as oncology, central nervous system, autoimmune diseases, metabolism, cardiovascular, and rare diseases, with the disease areas and modalities continuously expanding guided by the population disease profiles. Furthermore, GIC established a deep data-driven drug discovery platform based on bioinformatics and artificial intelligence (AI) techniques, a comprehensive protein medicine discovery and engineering platform, and a self-developed modular ADC toolbox and development platform, empowering efficient R&D of various innovative modalities.
